©2009 The WJG Press and Baishideng.
World J Gastroenterol. Aug 14, 2009; 15(30): 3713-3724
Published online Aug 14, 2009. doi: 10.3748/wjg.15.3713
Published online Aug 14, 2009. doi: 10.3748/wjg.15.3713
Table 5 Hepatotoxicity of highly active anti-retroviral therapy drugs and guidelines for their use in patients with liver disease
| Group | Drug | Dose adjustment |
| NRTI | Didanosine | Use cautiously |
| NNRTI | Delavirdine, Efavirenz, Nevirapine | Caution with hepatic impairment |
| PIs | Lopinavir, Nelfinavir, Ritonavir, Saquinavir | Caution with hepatic impairment |
| Atazanavir | Reduce 25% of dose in patients with CTP stage B and C | |
| Indinavir | Reduce dose by 25% in CTP stage B and C | |
| Tipranavir | Avoid in patients with CTP stage B or C | |
| Fosamprenavir | Avoid in patients with CTP stage C | |
| Darunavir | Avoid in patients with CTP stage C |
- Citation: Singal AK, Anand BS. Management of hepatitis C virus infection in HIV/HCV co-infected patients: Clinical review. World J Gastroenterol 2009; 15(30): 3713-3724
- URL: https://www.wjgnet.com/1007-9327/full/v15/i30/3713.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.3713